These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 1310748

  • 1. Phase I trial of granulocyte-macrophage colony-stimulating factor with high-dose cisplatin and etoposide for treatment of small-cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Shepherd FA, Goss PE, Rusthoven J, Eisenhauer EA.
    J Natl Cancer Inst; 1992 Jan 01; 84(1):59-60. PubMed ID: 1310748
    [No Abstract] [Full Text] [Related]

  • 2. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T.
    J Clin Oncol; 1997 May 01; 15(5):2082-9. PubMed ID: 9164221
    [Abstract] [Full Text] [Related]

  • 3. Clinical trials referral resource. Small-cell lung cancer.
    Cheson BD.
    Oncology (Williston Park); 1990 Jan 01; 4(1):43-56. PubMed ID: 2168198
    [No Abstract] [Full Text] [Related]

  • 4. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
    Ardizzoni A, Venturini M, Crinò L, Sertoli MR, Bruzzi P, Pennucci MC, Mariani GL, Garrone O, Bracarda S, Rosso R.
    Eur J Cancer; 1993 Jan 01; 29A(5):687-92. PubMed ID: 8385970
    [Abstract] [Full Text] [Related]

  • 5. Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate.
    Rosell R, Gómez-Codina J, Anton A, Sánchez JJ, Vadell C.
    Semin Oncol; 1994 Feb 01; 21(1 Suppl 1):48-53. PubMed ID: 8153657
    [No Abstract] [Full Text] [Related]

  • 6. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
    Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR, Cancer and Leukemia Group.
    J Clin Oncol; 2005 Jun 01; 23(16):3752-9. PubMed ID: 15923572
    [Abstract] [Full Text] [Related]

  • 7. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D.
    J Clin Oncol; 1999 Aug 01; 17(8):2300-8. PubMed ID: 10561291
    [Abstract] [Full Text] [Related]

  • 8. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
    Fukuoka M, Masuda N, Negoro S, Matsui K, Yana T, Kudoh S, Kusunoki Y, Takada M, Kawahara M, Ogawara M, Kodama N, Kubota K, Furuse K.
    Br J Cancer; 1997 Aug 01; 75(2):306-9. PubMed ID: 9010043
    [Abstract] [Full Text] [Related]

  • 9. [A combination chemotherapy of cisplatin and etoposide in small cell lung cancer].
    Saito R, Tsuchiya S, Minato K, Ishizuka T.
    Nihon Gan Chiryo Gakkai Shi; 1988 Mar 20; 23(3):744-51. PubMed ID: 2841389
    [No Abstract] [Full Text] [Related]

  • 10. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS.
    Clin Lung Cancer; 2003 Jul 20; 5(1):40-5. PubMed ID: 14596703
    [Abstract] [Full Text] [Related]

  • 11. Granulocyte-macrophage colony-stimulating factor in the treatment of small cell lung cancer.
    Wolf M, Klausmann M, Havemann K.
    Semin Oncol; 1994 Dec 20; 21(6 Suppl 16):51-6. PubMed ID: 7801147
    [No Abstract] [Full Text] [Related]

  • 12. Dose-intensive ifosfamide/carboplatin/etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer.
    Palackdharry CS, Krigel RL.
    Semin Oncol; 1994 Jun 20; 21(3 Suppl 4):6-11. PubMed ID: 8209278
    [Abstract] [Full Text] [Related]

  • 13. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
    J Clin Oncol; 1998 Feb 20; 16(2):642-50. PubMed ID: 9469353
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
    Kelly K, Lovato L, Bunn PA, Livingston RB, Zangmeister J, Taylor SA, Roychowdhury D, Crowley JJ, Gandara DR, Southwest Oncology Group.
    Clin Cancer Res; 2001 Aug 20; 7(8):2325-9. PubMed ID: 11489808
    [Abstract] [Full Text] [Related]

  • 15. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR.
    J Clin Oncol; 1995 Jul 20; 13(7):1632-41. PubMed ID: 7602352
    [Abstract] [Full Text] [Related]

  • 16. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
    Bunn PA, Kelly K.
    Semin Oncol; 1997 Aug 20; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
    [Abstract] [Full Text] [Related]

  • 17. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov 20; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 18. Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer.
    Hastürk S, Kurt B, Kocabas A, Orüç O, Burgut R.
    J Chemother; 1997 Feb 20; 9(1):66-71. PubMed ID: 9106021
    [Abstract] [Full Text] [Related]

  • 19. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, Satouchi M, Hida T, Yoshimura N, Kozuki T, Imamura F, Kiura K, Okamoto H, Sawa T, Tamura T, JCOG0605 investigators.
    Lancet Oncol; 2016 Aug 20; 17(8):1147-1157. PubMed ID: 27312053
    [Abstract] [Full Text] [Related]

  • 20. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L.
    Semin Oncol; 1995 Feb 20; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.